Family‐Borne Financial Costs of Managing Paediatric Haemophilia in a Government Facility in North India
Haemophilia · 2026
DOI: 10.1111/hae.70167 ↗Kurz gefasst
Fachartikel in der Zeitschrift Haemophilia, 2026. Verfasst von Nita Radhakrishnan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Hematology Oncology, Post Graduate Institute of Child Health, Noida, India. Hauptthemen laut MEDLINE: Hemophilia A, Cost of Illness. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
Background
In India, persons with haemophilia (PWH) are entitled to free diagnostic services, clotting‐factor concentrates and physiotherapy. However, families often continue to experience substantial financial hardships for regular treatment. This study aimed to quantify the expenditure borne by such families of PWH treated at our centre and identify contributing factors.
Methods
At our state‐supported haemophilia treatment centre, we assessed costs related to travel, wage loss and ancillary diagnostics and medications. A structured questionnaire, adapted from the cost of haemophilia in Europe: A socioeconomic survey (CHESS), was developed, piloted and pretested. Institutional ethics approval was obtained, and informed consent was taken.
Results
Between 2022 and 2023, 250 caregivers out of 800 registered PWH were interviewed. Among the respondents, 74% belonged to lower socioeconomic strata and 38% were daily‐wage earners. Approximately 40% travelled > 100 km per bleeding episode. Educational disruption was reported in 5.6% of PWH. Forty‐six per cent experienced frequent interruptions; 66% noted adverse effects on siblings' education. While clotting factors were provided free of cost, 61% spent at least ₹500 per visit, with wage losses ranging from ₹500 to ₹5000 per episode. Income loss among caregivers was reported by 85%. Eighty‐seven per cent experienced moderate to extreme financial stress. A broader impact on household economics, including food and education, was noted in 69% of families. Only 5% had access to health insurance.
Conclusions
Despite free treatment provisions, haemophilia care imposes a significant financial burden. Prophylaxis with home therapy could mitigate these challenges. Incorporating hidden costs into health economic evaluations is essential for informed policy in resource‐limited settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatric Hematology Oncology, Post Graduate Institute of Child Health, Noida, India.
- ICON Plc, , India.
Zitieren
APA
Radhakrishnan, N., Pandharipande, A., Gupta, R., Verma, S., Baby, E. P., Gaire, H., & Singh, M. (2026). Family‐Borne Financial Costs of Managing Paediatric Haemophilia in a Government Facility in North India. Haemophilia. https://doi.org/10.1111/hae.70167
Vancouver
Radhakrishnan N, Pandharipande A, Gupta R, Verma S, Baby EP, Gaire H, et al. Family‐Borne Financial Costs of Managing Paediatric Haemophilia in a Government Facility in North India. Haemophilia. 2026. doi:10.1111/hae.70167
BibTeX
@article{Radhakrishnan2026,
author = {Radhakrishnan, Nita and Pandharipande, Archit and Gupta, Ritu and Verma, Shruti and Baby, Eby P and Gaire, Hari and Singh, Manju},
title = {Family‐Borne Financial Costs of Managing Paediatric Haemophilia in a Government Facility in North India},
journal = {Haemophilia},
year = {2026},
doi = {10.1111/hae.70167}
}
EUVIMED